Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$36.5 - $52.5 $7,519 - $10,815
-206 Reduced 5.31%
3,670 $180,000
Q4 2023

Feb 14, 2024

BUY
$18.94 - $37.24 $9,697 - $19,066
512 Added 15.22%
3,876 $141,000
Q3 2023

Nov 14, 2023

BUY
$23.12 - $31.38 $4,138 - $5,617
179 Added 5.62%
3,364 $77,000
Q2 2023

Aug 10, 2023

BUY
$23.15 - $32.71 $73,732 - $104,181
3,185 New
3,185 $83,000
Q4 2022

Jun 14, 2023

BUY
$21.73 - $28.72 $46,806 - $61,862
2,154 New
2,154 $56 Million
Q4 2022

Mar 30, 2023

BUY
$21.73 - $28.72 $5,389 - $7,122
248 Added 13.01%
2,154 $56,000
Q4 2022

Feb 15, 2023

BUY
$21.73 - $28.72 $5,389 - $7,122
248 Added 13.01%
2,154 $56,000
Q3 2022

Jun 14, 2023

BUY
$24.1 - $39.66 $45,934 - $75,591
1,906 New
1,906 $54.4 Million
Q2 2022

Jun 20, 2023

BUY
$18.36 - $60.07 $34,994 - $114,493
1,906 New
1,906 $46,000
Q1 2022

Jun 20, 2023

BUY
$48.97 - $65.46 $93,336 - $124,766
1,906 New
1,906 $107,000
Q1 2022

Mar 30, 2023

SELL
$48.97 - $65.46 $270,755 - $361,928
-5,529 Reduced 74.36%
1,906 $107,000
Q1 2022

May 12, 2022

SELL
$48.97 - $65.46 $270,755 - $361,928
-5,529 Reduced 74.36%
1,906 $108,000
Q4 2021

Jun 21, 2023

BUY
$53.3 - $75.84 $396,285 - $563,870
7,435 New
7,435 $460,000
Q4 2021

Mar 30, 2023

SELL
$53.3 - $75.84 $34,325 - $48,840
-644 Reduced 7.97%
7,435 $460,000
Q4 2021

Feb 15, 2022

SELL
$53.3 - $75.84 $34,325 - $48,840
-644 Reduced 7.97%
7,435 $461,000
Q3 2021

Jun 21, 2023

BUY
$62.66 - $88.26 $506,230 - $713,052
8,079 New
8,079 $512,000
Q2 2021

Mar 30, 2023

BUY
$67.45 - $85.63 $110,618 - $140,433
1,640 Added 25.47%
8,079 $665,000
Q2 2021

Aug 16, 2021

BUY
$67.45 - $85.63 $544,523 - $691,290
8,073 Added 134550.0%
8,079 $666,000
Q1 2021

Jun 26, 2023

BUY
$65.1 - $93.59 $419,178 - $602,626
6,439 New
6,439 $474 Million
Q1 2021

Mar 30, 2023

SELL
$65.1 - $93.59 $14,126 - $20,309
-217 Reduced 3.26%
6,439 $473,000
Q1 2021

May 14, 2021

SELL
$65.1 - $93.59 $432,914 - $622,373
-6,650 Reduced 99.91%
6 $474,000
Q4 2020

Jun 22, 2023

BUY
$48.36 - $77.92 $321,884 - $518,635
6,656 New
6,656 $482,000
Q3 2020

Jun 26, 2023

BUY
$36.14 - $51.99 $240,547 - $346,045
6,656 New
6,656 $317,000
Q2 2020

Jun 26, 2023

BUY
$22.98 - $48.57 $152,954 - $323,281
6,656 New
6,656 $279,000
Q2 2020

Mar 30, 2023

BUY
$22.98 - $48.57 $71,973 - $152,121
3,132 Added 88.88%
6,656 $279,000
Q2 2020

Aug 14, 2020

BUY
$22.98 - $48.57 $71,973 - $152,121
3,132 Added 88.88%
6,656 $280,000
Q1 2020

Jul 12, 2023

BUY
$20.44 - $41.21 $72,030 - $145,224
3,524 New
3,524 $95,000
Q1 2020

Mar 30, 2023

SELL
$20.44 - $41.21 $47,747 - $96,266
-2,336 Reduced 39.86%
3,524 $95,000
Q1 2020

May 15, 2020

SELL
$20.44 - $41.21 $47,747 - $96,266
-2,336 Reduced 39.86%
3,524 $95,000
Q4 2019

Jul 12, 2023

BUY
$17.74 - $39.52 $103,956 - $231,587
5,860 New
5,860 $225,000
Q4 2019

Mar 30, 2023

BUY
$17.74 - $39.52 $65,744 - $146,461
3,706 Added 172.05%
5,860 $225,000
Q4 2019

Feb 14, 2020

BUY
$17.74 - $39.52 $103,956 - $231,587
5,860 New
5,860 $226,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $1.87B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.